A NEW study has revealed how the protein Rab7a enhances the activity of TPC2, a cellular channel linked to melanoma, the deadliest form of skin cancer. Researchers have pinpointed the GSK3β/β-Catenin/MITF signaling pathway as a critical mechanism influenced by this interaction, shedding light on potential therapeutic targets.
Melanoma, originating from pigment-producing melanocytes, is a high-risk cancer, especially in individuals with low melanin levels. TPC2 has been identified as a vital regulator of melanoma proliferation and progression. However, the new research shows that Rab7a acts as a powerful enhancer of TPC2, influencing cellular processes that drive tumor growth, migration, and invasion.
In the study, Rab7a’s modulation of TPC2 activity impacted key melanoma drivers, including the GSK3β/β-Catenin/MITF axis, a major pathway involved in tumor development. Intriguingly, when TPC2 function was diminished, melanoma cells showed reduced aggressiveness and increased pigmentation, suggesting a potential therapeutic strategy.
This discovery opens new avenues for targeting TPC2 and Rab7a in melanoma treatment, offering hope for more effective interventions against this aggressive cancer type.
Reference: Abrahamian C et al. Rab7a is an enhancer of TPC2 activity regulating melanoma progression through modulation of the GSK3β/β-Catenin/MITF-axis. Nat Commun. 2024;15(10008).
